CorMedix [CRMD] vs Regeneron [REGN] Detailed Stock Comparison
CorMedix
NASDAQ
Loading...
Regeneron
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: CorMedix wins in 9 metrics, Regeneron wins in 10 metrics, with 0 ties. Regeneron appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | CorMedix | Regeneron | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 15.90 | 14.45 | Regeneron |
| Price-to-Book Ratio | 4.19 | 1.99 | Regeneron |
| Debt-to-Equity Ratio | 0.20 | 9.04 | CorMedix |
| PEG Ratio | -0.07 | 12.65 | CorMedix |
| EV/EBITDA | 14.75 | 12.24 | Regeneron |
| Profit Margin (TTM) | 42.11% | 31.37% | CorMedix |
| Operating Margin (TTM) | 49.18% | 29.64% | CorMedix |
| EBITDA Margin (TTM) | 49.18% | 29.64% | CorMedix |
| Return on Equity | 38.35% | 15.34% | CorMedix |
| Return on Assets (TTM) | 19.87% | 6.66% | CorMedix |
| Free Cash Flow (TTM) | $-50.73M | $3.54B | Regeneron |
| Dividend Yield | N/A | 0.46% | N/A |
| 1-Year Return | 87.48% | -51.75% | CorMedix |
| Price-to-Sales Ratio (TTM) | 7.62 | 4.28 | Regeneron |
| Enterprise Value | $735.37M | $54.69B | Regeneron |
| EV/Revenue Ratio | 6.05 | 3.85 | Regeneron |
| Gross Profit Margin (TTM) | 95.31% | 85.58% | CorMedix |
| Revenue per Share (TTM) | $2 | $133 | Regeneron |
| Earnings per Share (Diluted) | $0.78 | $39.68 | Regeneron |
| Beta (Stock Volatility) | 1.77 | 0.35 | Regeneron |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
CorMedix vs Regeneron Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| CorMedix | 2.20% | -11.00% | 29.39% | -9.20% | 21.44% | 58.52% |
| Regeneron | -0.34% | -3.70% | 1.94% | 7.52% | -25.28% | -22.18% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| CorMedix | 87.48% | 285.50% | 182.65% | -11.06% | 59.88% | 5.93% |
| Regeneron | -51.75% | -21.65% | 0.23% | 1.12% | 2,000.11% | 6,565.03% |
News Based Sentiment: CorMedix vs Regeneron
CorMedix
News based Sentiment: POSITIVE
The acquisition of Melinta Therapeutics, coupled with significantly raised financial guidance and strong Q2 earnings, represents a game-changing month for CorMedix. The company is demonstrating successful integration and a clear path to future growth, making it a compelling investment story.
Regeneron
News based Sentiment: MIXED
September presented a mixed bag for Regeneron, with positive Phase 3 trial results for new allergy treatments and continued growth in existing products being offset by regulatory delays for EYLEA HD and a cautious market response. The company is actively working to address these challenges, but the overall investment story remains complex.
Performance & Financial Health Analysis: CorMedix vs Regeneron
| Metric | CRMD | REGN |
|---|---|---|
| Market Information | ||
| Market Cap | $989.65M | $60.77B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 5,929,790 | 993,280 |
| 90 Day Avg. Volume | 4,167,210 | 992,680 |
| Last Close | $13.03 | $556.53 |
| 52 Week Range | $5.37 - $17.43 | $476.49 - $1,170.58 |
| % from 52W High | -25.24% | -52.46% |
| All-Time High | $52.00 (Mar 30, 2015) | $1,211.20 (Aug 26, 2024) |
| % from All-Time High | -74.94% | -54.05% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 48.29% | 0.04% |
| Quarterly Earnings Growth | 48.29% | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.42% | 0.31% |
| Operating Margin (TTM) | 0.49% | 0.30% |
| Return on Equity (TTM) | 0.38% | 0.15% |
| Debt to Equity (MRQ) | 0.20 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.96 | $287.55 |
| Cash per Share (MRQ) | $2.56 | $72.04 |
| Operating Cash Flow (TTM) | $30.46M | $4.74B |
| Levered Free Cash Flow (TTM) | $10.70M | $2.85B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.46% |
| Last 12-Month Dividend | N/A | $2.64 |
Valuation & Enterprise Metrics Analysis: CorMedix vs Regeneron
| Metric | CRMD | REGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 15.90 | 14.45 |
| Forward P/E | 25.83 | 12.65 |
| PEG Ratio | -0.07 | 12.65 |
| Price to Sales (TTM) | 7.62 | 4.28 |
| Price to Book (MRQ) | 4.19 | 1.99 |
| Market Capitalization | ||
| Market Capitalization | $989.65M | $60.77B |
| Enterprise Value | $735.37M | $54.69B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.05 | 3.85 |
| Enterprise to EBITDA | 14.75 | 12.24 |
| Risk & Other Metrics | ||
| Beta | 1.77 | 0.35 |
| Book Value per Share (MRQ) | $2.96 | $287.55 |
Financial Statements Comparison: CorMedix vs Regeneron
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CRMD | REGN |
|---|---|---|
| Revenue/Sales | $39.08M | $3.03B |
| Cost of Goods Sold | $1.60M | $464.30M |
| Gross Profit | $37.48M | $2.56B |
| Research & Development | $3.19M | $1.34B |
| Operating Income (EBIT) | $20.13M | $591.70M |
| EBITDA | $20.85M | $900.90M |
| Pre-Tax Income | $20.64M | $905.00M |
| Income Tax | $0 | $96.30M |
| Net Income (Profit) | $20.64M | $808.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CRMD | REGN |
|---|---|---|
| Cash & Equivalents | $66.29M | $3.09B |
| Total Current Assets | $144.86M | $17.57B |
| Total Current Liabilities | $34.39M | $3.57B |
| Long-Term Debt | $304,092 | $2.70B |
| Total Shareholders Equity | $114.89M | $29.39B |
| Retained Earnings | $-318.99M | $32.38B |
| Property, Plant & Equipment | $2.18M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CRMD | REGN |
|---|---|---|
| Operating Cash Flow | $21.67M | $1.36B |
| Capital Expenditures | $-10,177 | N/A |
| Free Cash Flow | $19.73M | $773.60M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-1.05B |
Short Interest & Institutional Ownership Analysis
| Metric | CRMD | REGN |
|---|---|---|
| Shares Short | 14.18M | 2.35M |
| Short Ratio | 4.77 | 2.36 |
| Short % of Float | 0.19% | 0.02% |
| Average Daily Volume (10 Day) | 5,929,790 | 993,280 |
| Average Daily Volume (90 Day) | 4,167,210 | 992,680 |
| Shares Outstanding | 64.41M | 109.62M |
| Float Shares | 69.27M | 97.89M |
| % Held by Insiders | 0.07% | 0.02% |
| % Held by Institutions | 0.47% | 0.90% |
Dividend Analysis & Yield Comparison: CorMedix vs Regeneron
| Metric | CRMD | REGN |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.64 |
| Last 12-Month Dividend Yield | N/A | 0.46% |
| 3-Year Avg Annual Dividend | N/A | $0.88 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | $2.64 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |